Mortality, hospitalization, and quality of life among patients with hepatitis c infection on hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 2, 2017, Pages 287-297

  Goodkin, David A ^a   Bieber, Brian ^a   Jadoul, Michel ^b   Martin, Paul ^c   Kanda, Eiichiro ^d   Pisoni, Ronald L ^a  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF MIAMI   (United States)

^d TOKYO KYOSAI HOSPITAL   (Japan)

Author keywords

Adult; Anemia; Anorexia; Antiviral agents; Creatinine; Depression; Epidemiologic studies; Erythrocyte transfusion; Follow up studies; Health; Hemoglobins; Hepacivirus; Hepatitis B; Hepatitis C; Hospitalization; Humans; Incidence; Kidney diseases; Mental; Mortality; Pain; Phosphorus; Prevalence; Quality of life; Renal dialysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN; PHOSPHORUS; SERUM ALBUMIN; ANTIVIRUS AGENT;

ADULT; ANEMIA; ANOREXIA; ARTICLE; CHRONIC HEPATITIS B; CONTROLLED STUDY; DEPRESSION; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; LENGTH OF STAY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIDDLE AGED; MORTALITY; MORTALITY RISK; PAIN; PATIENT-REPORTED OUTCOME; PREVALENCE; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; AGED; BLOOD; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COMORBIDITY; HOSPITALIZATION; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ALANINE TRANSAMINASE; ANEMIA; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; FEMALE; HEPATITIS C; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; RENAL DIALYSIS;

EID: 85018011406     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07940716     Document Type: Article

References (39)

1. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M: Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 38: 405-412, 2013
2. Health Advisory CDC: CDC Urging Dialysis Providers and Facilities to Assess and Improve Infection Control Practices to Stop Hepatitis C Virus Transmission in Patients Undergoing Hemodialysis. 2016. Available at: http://emergency.cdc.gov/han/ han00386.asp. Accessed March 14, 2016
3. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held P: The dialysis outcomes and practice patterns study: An international hemodialysis study. Kidney Int 57: S74-S81, 2000
4. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA: The dialysis outcomes and practice patterns study (DOPPS): Design, data elements, and methodology. Am J Kidney Dis 44[Suppl 2]: 7-15, 2004
5. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 3: 329-338, 1994
6. Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley J: Two shorter forms of the CES-D depression symptoms index. J Aging Health 5: 179-193, 1993
7. Andresen EM, Malmgren JA, Carter WB, Patrick DL: Screening for depression in well older adults: Evaluation of a short form of the CES-D (Center for Epidemiologic StudiesDepression Scale). AmJ Prev Med 10: 77-84, 1994
8. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341: 556-562, 1999
9. AASLD/IDSA HCV Guidance Panel: Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62: 932-954, 2015
10. Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, Xu F, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators: Mortality among persons in care with hepatitis C virus infection: The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis 58: 1055-1061, 2014
11. Oramasionwu CU, Toliver JC, Johnson TL, Moore HN, Frei CR: National trends in hospitalization and mortality rates for patients with HIV, HCV, or HIV/HCV coinfection from 1996-2010 in the United States: A cross-sectional study. BMC Infect Dis 14: 536, 2014
12. Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 27: 209-212, 1998
13. Bonkovsky HL, Woolley JM; The Consensus Interferon Study Group: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 29: 264-270, 1999
14. Ware Jr JE, Bayliss MS, Mannocchia M, Davis GL; The Interventional Therapy Group: Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology 30: 550-555, 1999
15. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Gerber L, Nader F, Hunt S: Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 12: 1349-1359.e13, 2014
16. Pereira BJG, Natov SN, Bouthot BA, Murthy BVR, Ruthazer R, Schmid CH, Levey AS: Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 53: 1374-1381, 1998
17. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ: Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 32: 629-634, 1998
18. Nakayama E, Akiba T, Marumo F, Sato C: Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 11: 1896-1902, 2000
19. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P: Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 16: 1669-1674, 2001
20. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S: Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 18: 1584-1593, 2007
21. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang C-C, Han D-S, Jha V, Wang T, Kawaguchi Y, Qian J: Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: Analysis of registry data. Nephrol Dial Transplant 24: 1598-1603, 2009
22. Abdalla AH, Owda AK, Fedail H, Popovich WF, Mousa D, Al-Hawas F, Al-Sulaiman M, Al-Khader AA: Influence of hepatitis C virus infection upon parenteral iron and erythropoietin responsiveness in regular haemodialysis patients. Nephron 84: 293-294, 2000
23. Sahin I, Arabaci F, Sahin HA, Ilhan M, Ustun Y, Mercan R, Eminov L: Does hepatitis C virus infection increase hematocrit and hemoglobin levels in hemodialyzed patients? Clin Nephrol 60: 401-404, 2003
24. Altintepe L, Kurtoglu E, Tonbul Z, Yeksan M, Yildiz A, Türk S: Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection. Clin Nephrol 61: 347-351, 2004
25. Khurana A, Nickel AE, Narayanan M, Foulks CJ: Effect of hepatitis C infection on anemia in hemodialysis patients. Hemodial Int 12: 94-99, 2008
26. Afsar B, Elsurer R, Sezer S, Ozdemir NF: Quality of life in hemodialysis patients: Hepatitis C virus infection makes sense. Int Urol Nephrol 41: 1011-1019, 2009
27. Rostami Z, Pezeshki ML, Abadi ASN, Einollahi B: Health related quality of life in Iranian hemodialysis patients with viral hepatitis: Changing epidemiology. Hepat Mon 2013. Available at http:// hepatmon.com/9611.fulltext. Accessed March 22, 2016
28. Levy C: Management of pruritus in patients with cholestatic liver disease. Gastroenterol Hepatol (N Y) 7: 615-617, 2011
29. Kidney Disease: Improving Global Outcome: KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int 73 [Suppl 109]: S1-S99, 2008
30. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB: Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection:Asystematic reviewof the literature andmeta-analysis of treatment efficacy and harms. AmJ KidneyDis 51: 263-277, 2008
31. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G: Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies. Am J Transplant 5: 1452-1461, 2005
32. Goodkin DA, Bieber B: Hemodialysis patients with hepatitis C infection are not receiving the new antiviral medications. Am J Nephrol 41: 302, 2015
33. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londoño M-C, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen B-Y, Robertson M, Barr E, Wahl J, Greaves W: Grazoprevir plus elbasvir in treatmentnaive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study. Lancet 386: 1537-1545, 2015
34. Morales JM, Campistol JM, Domínguez-Gil B, Andrés A, Esforzado N, Oppenheimer F, Castellano G, Fuertes A, Bruguera M, Praga M: Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant 10: 2453-2462, 2010
35. Roberts K, Macleod J, Metcalfe C, Simon J, Horwood J, Hollingworth W, Marlowe S, Gordon FH, Muir P, Coleman B, Vickerman P, Harrison GI, Waldron C-A, Irving W, Hickman M: Hepatitis C-Assessment to Treatment Trial (HepCATT) in primary care: Study protocol for a cluster randomised controlled trial. Trials 17: 366, 2016
36. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB: Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 11: 1503-1510, 2013
37. Guh J-Y, Lai Y-H, Yang C-Y, Chen S-C, Chuang W-L, Hsu T-C, Chen H-C, Chang W-Y, Tsai J-H: Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 69: 459-465, 1995
38. Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, Locatelli F: Decreased serum aminotransferase activity in patients with chronic renal failure: Impact on the detection of viral hepatitis. Am J Kidney Dis 38: 1009-1015, 2001
39. Contreras AM, Ruiz I, Polanco-Cruz G, Monteón FJ, Celis A, Vázquez G, Gómez-Herrera E, García-Correa JE, Male-Velázquez R, Ruelas-Hernández S: End-stage renal disease and hepatitis C infection: Comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. Ann Hepatol 6: 48-54, 2007